<DOC>
	<DOCNO>NCT00002298</DOCNO>
	<brief_summary>The objective clinical trial determine whether long-term oral dosage ribavirin delay development symptomatic HIV disease HIV antibody positive subject completely asymptomatic ( CDC classification group II ) , lymphadenopathy syndrome ( CDC classification group III ) , clinical symptom severe HIV disease define CDC classification , whether dosage regimen safe tolerable subject .</brief_summary>
	<brief_title>The Safety Effectiveness Ribavirin Early Stages HIV-Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acyclovir . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : CDC classification group IV A ( ARC ) . CDC classification group IV C1 ( AIDS ) IV C2 ( include Thrush Herpes zoster past 2 year ) . Positive plasma p24 antigen . Unstable medical condition , include serious cardiovascular , renal , hepatic , neurologic , infectious , oncologic condition even unrelated HIV infection . Splenectomy . Concurrent Medication : Excluded : Isoprinosine . Patients follow exclude : Failure give inform consent . CDC classification group IV A ( ARC ) . CDC classification group IV C1 ( AIDS ) IV C2 ( include Thrush Herpes zoster past 2 year ) . Positive plasma p24 antigen . Unstable medical condition , include serious cardiovascular , renal , hepatic , neurologic , infectious , oncologic condition even unrelated HIV infection . Splenectomy . Prior Medication : Excluded within 4 week start screen test : Zidovudine . Other drug scientifically accept antiHIV property . Scientifically accept immunostimulant treatment . Immunosuppressant . Myelosuppressant know toxic drug . HIV infection group II ( CDC ) , asymptomatic HIV infection . HIV antibody positive Western blot antibody p24 band GP160 band and/or GP41 . Two positive test screen require . CDC HIV infection group II , asymptomatic HIV infection , define Appendix A , CDC HIV infection group III , persistent generalize lymphadenopathy ( PGL , formerly LAS ) . OKT4+ lymphocyte count great 300 cells/mm3 less 600 cells/mm3 . The count determine three separate evaluation separate least 7 day evaluation . These three count average inclusion study mean OKT4+ lymphocyte count must great 200 cells/mm3 less 600 cells/mm3 . Conclusion screen test : Within 42 day start . Patients must enter study within 14 day screen completion . Ability participate outpatient : Ambulatory , competent sign inform consent , able cooperate treatment plan evaluation schedule . Informed consent : Must sign randomization treatment . Physical activity evaluation Karnofsky score great equal 90 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 1998</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>